Omega Therapeutics, Inc. functions as a biopharmaceutical firm in its development phase. Its innovative OMEGA Epigenomic Programming platform leverages epigenetics—nature's fundamental system for gene regulation and cell differentiation—to engineer therapeutic solutions. The company is advancing various omega epigenomic controller (OEC) candidates to tackle a spectrum of diseases. These candidates are designed to enhance the expression of HNF4a, a crucial transcriptional master regulator, aiming to restore liver cell function in patients with chronic liver ailments. They also work to promote corneal regeneration in those with diabetes and other conditions by regulating genes associated with inhibiting cell growth. Furthermore, OECs are being developed to reduce the expression of the CXCL1, 2, 3, and IL-8 gene cluster for inflammatory diseases, and to manage gene expression implicated in idiopathic pulmonary fibrosis, seeking to arrest or reverse disease progression and improve patient outcomes. Other targets include down-regulating SFRP1, a protein known to hinder hair growth, and addressing both non-small cell and small cell lung cancers. Additionally, Omega Therapeutics is progressing OTX-2002, an investigational treatment intended to diminish the activity of c-Myc, an oncogene. Incorporated in 2016, the company's main operations are based in Cambridge, Massachusetts.